Minimally invasive physiological function monitoring agents
AssigneeMallinckrodt Inc.
InventorsSamuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
Life of this patent
Estimating the term…
Abstract
Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
Claims33
A compound having the formula
- 11
- wherein R37, R38, R39, R40, R41, R42, R43, R44 and R45, Y5, and Z5 are independently selected from the group consisting of —H, C1-C10 alkoxyl, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, glucose derivatives of R groups, saccharides, amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C1-C10 alkyl, C5-C20 aryl, —SO3T, —CO2T, —OH, —(CH2)aSO3T, —(CH2)aOSO3T, —(CH2)aNHSO3T, —(C H2)aCO2(CH2)bSO3T, —(CH2)aOCO(CH2)bSO3T, —(CH2)aCONH(CH2)bSO3T, —(CH2)aNHCO(CH2)bSO3T, —(CH2)aNHCONH(CH2)bSO3T, —(CH2)aNHCSNH(CH2)bSO3T, —(CH2)aOCONH(CH2)bSO3T, —(CH2)aPO3HT, —(CH2)aPO3T2, —(CH2)aOPO3HT, —(CH2)aOPO3T2, —(CH2)aNHPO3HT, —(CH2)aNHPO3T2, —(CH2)aCO2(CH2)bPO3HT, —(CH2)aCO2(CH2)bPO3T2, —(CH2)aOCO(CH2)bPO3HT, —(CH2)aOCO(CH2)bPO3T2, —(CH2)aCONH(CH2)bPO3HT, —(CH2)aCONH(CH2)bPO3T2, —(CH2)aNHCO(CH2)bPO3HT, —(CH2)aNHCO(CH2)bPO3T2, —(CH2)aNHCONH(CH2)bPO3HT, —(CH2)aNHCONH(CH2)bPO3T2, —(CH2)aNHCSNH(CH2)bPO3HT, —(CH2)aNHCSNH(CH2)bPO3T2, —(CH2)aOCONH(CH2)bPO3HT, and —(CH2)aOCONH(CH2)bPO3T2, —CH2(CH2—O—CH2)c—CH2—OH, —(CH2)d—CO2T, —CH2—(CH2—O—CH2)e—CH2—CO2T, —(CH2)—NH2—CH2—(CH2—O—CH2)g—CH2—NH2, —(CH2)h—N(Ra)—(CH2)i—CO2T, and —(CH2)j—N(Rb)—CH2—(CH2—O—CH2)k—CH2—CO2T;
- W5 and X5 are selected from the group consisting of —O—, —NRc, and —S—;
- V5 is a single bond or is selected from the group consisting of —O—, —S—, —Se—, and —NRa;
- D5 is a single or a double bond;
- A5 and B5 are independently selected from —O—, —S—, —Se—, —P—, —NRa, —CRcRd, alkyl, and —C═O;
- E5 is independently selected from —S—, —Se—;
- —P—, —NRa, CRcRd, —CRc, alkyl, and —C═O;
- A5, B5, D5, and E5 may together form a 6 or 7 membered carbocyclic ring or a 6 or 7 membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom;
- a, b, d, f, h, i, and j independently vary from 1-10;
- c, e, g, and k independently vary from 1-100;
- a5 and b5 vary from 0 to 5;
- Ra, Rb, Rc, and Rd are defined in the same manner as Y5;
- and T is either H or a negative charge.
A composition comprising a compound of formula
- 12
- wherein R37, R38, R39, R40, R41, R42, R43, R44 and R45, Y5, and Z5 are independently selected from the group consisting of —H, C1-C10 alkoxyl, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, glucose derivatives of R groups, saccharides, amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C1-C10 alkyl, C5-C20 aryl, —SO3T, —CO2T, —OH, —(CH2)aSO3T, —(CH2)aOSO3T, —(CH2)aNHSO3T, —(CH2)aCO2(CH2)bSO3T, —(CH2)aOCO(CH2)bSO3T, —(CH2)aCONH(CH2)bSO3T, —(CH2)aNHCO(CH2)bSO3T, —(CH2)aNHCONH(CH2)bSO3T, —(CH2)aNHCSNH(CH2)bSO3T, —(CH2)aOCONH(CH2)bSO3T, —(CH2)aPO3HT, —(CH2)aPO3T2, —(CH2)aOPO3HT, —(CH2)aOPO3T2, —(CH2)aNHPO3HT, —(CH2)aNHPO3T2, —(CH2)aCO2(CH2)bPO3HT, —(CH2)aCO2(CH2)bPO3T2, —-(CH2)aOCO(CH2)bPO3HT, —(CH2)aOCO(CH2)bPO3T2, —(CH2)aCONH(CH2)bPO3HT, —(CH2)aCON H(CH2)bPO3T2, —(CH2)aNHCO(CH2)bPO3HT, —(CH2)aNHCO(CH2)bPO3T2, —(CH2)aNHCONH(CH2)bPO3HT, —CH2)aNHCONH(CH2)bPO3T2, —(CH2)aNHCSNH(CH2)bPO3HT, —(CH2)aNHCSNH(CH2)bPO3T2, —(CH2)aOCONH(CH2)bPO3HT, and —(CH2)aOCONH(CH2)bPO3T2, —CH2(CH2—O—CH2)c—CH2—OH, —(CH2)d—CO2T, —CH2—(CH2—O—CH2)eCH2—CO2T, —(CH2)f—NH2, —CH2—(CH2—O—CH2)g—CH2—NH2, —CH2)h—N(Ra)—(CH2)i—CO2T, and —(CH2)j—N(Rb)—CH2—(CH2—O—CH2)k—CH2—CO2T;
- W5 and X5 are selected from the group consisting of —O—, —NRc, —S—, and —Se;
- V5 is a single bond or is selected from the group consisting of —O—, —S—, —Se—, and —NRa;
- D5 is a single or a double bond;
- A5 and B5 are independently selected from —O—, —S—, —Se—, —P—, —NRa, —CRcRd, alkyl, and —C═O;
- E5 is independently selected from —S—, —Se—;
- —P—, —NRa, CRcRd, —CRc, alkyl, and —C═O;
- A5, B5, D5, and E5 may together form a 6 or 7 membered carbocyclic ring or a 6 or 7 membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom;
- a, b, d, f, h, i, and j independently vary from 1-10;
- c, e, g, and k independently vary from 1 -100;
- a5 and b5 vary from 0 to 5;
- Ra, Rb, Rc, and Rd are defined in the same manner as Y5;
- and T is either H or a negative charge, in a pharmaceutically acceptable composition.
A method for performing a diagnostic or therapeutic procedure comprising administering to a mammal an effective amount of a compound of formula
- 13
- in a pharmaceutically acceptable composition wherein R37, R38, R39, R40, R41, R42, R43, R44 and R45, Y5, and Z5 are independently selected from the group consisting of —H, C1-C10 alkoxyl, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, glucose derivatives of R groups, saccharides, amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C1-C10 alkyl, C5-C20 aryl, —SO3T, —CO2T, —OH, —(CH2)aSO3T, —(CH2)aOSO3T, —(CH2)aNHSO3T, —(CH2)aCO2(CH2)bSO3T, —(CH2)aOCO(CH2)bSO3T, —(CH2)aCONH(CH2)bSO3T, —(CH2)aNHCO(CH2)bSO3T, —(CH2)aNHCONH(CH2)bSO3T, —(CH2)—NHCSNH(CH2)bSO3T, —(CH2)aOCONH(CH2)bSO3T, —(CH2)aPO3HT, —(CH2)aPO3T2, —(CH2)aOPO3HT, —(CH2)aOPO3T2, —(CH2)aNHPO3HT, —(CH2)aNHPO3T2, —(CH2)aCO2(CH2)bPO3HT, —(CH2)aCO2(CH2)bPO3T2, —(CH2)aOCO(CH2)bPO3HT, —(CH2)aOCO(CH2)bPO3T2, —(CH2)aCONH(CH2)bPO3HT, —(CH2)aCONH(CH2)bPO3T2, —(CH2)aNHCO(CH2)bPO3HT, —(CH2)aNHCO(CH2)bPO3T2, —(CH2)aNHCONH(CH2)bPO3HT, —(CH2)aNHCONH(CH2)bPO3T2, —(CH2)aNHCSNH(CH2)bPO3HT, —(CH2)aNHCSNH(CH2)bPO3T2, —(CH2)aOCONH(CH2)bPO3HT, and —(CH2)aOCONH(CH2)bPO3T2, —CH2(CH2—O—CH2)c—CH2—OH, —(CH2)d—CO2T, —CH2—(CH2—O—CH2)e—CH2—CO2T, —(CH2)f—NH2, —CH2—(CH2—O—CH2)g—CH2—NH2, —(CH2)hN(Ra)—(CH2)i—CO2T, and —(CH2)j—N(Rb)—CH2(CH2—O—CH2)k—CH2—CO2T;
- W5 and X5 are selected from the group consisting of —O—, —NRc, —S—, and —Se;
- V5 is a single bond or is selected from the group consisting of —O—, —S—, —Se—, and —NRa;
- D5 is a single or a double bond;
- A5 and B5 are independently selected from the group consisting of —O—, —S—, —Se—, —P—, —NRa, —CRcRd, alkyl, and —C═O;
- E5 is independently selected from —S—, —Se—;
- —P—, —NRa, CRcRd, —CRc, alkyl, and —C═O;
- A5, B5, D5, and E5 may together form a 6 or 7 membered carbocyclic ring or a 6 or 7 membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atoms;
- a, b, d, f, h, i, and j independently vary from 1-10;
- c, e, g, and k independently vary from 1-100;
- a5 and b5 vary from 0 to 5;
- Ra, Rb, Rc, and Rd are defined in the same manner as Y5;
- and T is either H or a negative charge, and performing the diagnostic or therapeutic procedure.
Dependencies are inferred from the claim text.